BAT8006 for Injection

DRUG2 trials

Sponsors

Bio-Thera Solutions

Conditions

Advanced Solid TumorsFallopian Tube CancerPlatinum-resistant Epithelial Ovarian CancerPrimary Peritoneal Cancer

Phase 1

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

CompletedNCT05378737

Bio-Thera SolutionsAdvanced Solid Tumors

Start: 2022-07-06End: 2025-12-08Updated: 2026-01-06

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

WithdrawnNCT06545617

Bio-Thera SolutionsFallopian Tube Cancer, Platinum-resistant Epithelial Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-01-31End: 2028-01-31Updated: 2026-01-07

Related Papers

Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.

Journal of Clinical Oncology2025-05-28

Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors.

Journal of Clinical Oncology2024-06-014 citations